According to TipRanks.com, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.7% and a 35.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $236.83, which is an 11.4% upside from current levels. In a report issued on July 20, Piper Sandler also maintained a Hold rating on the stock with a $200.00 price target.
Based on Biogen’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.59 billion and net profit of $1.06 billion. In comparison, last year the company earned revenue of $2.78 billion and had a net profit of $449 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
Read More on BIIB: